Complement activation in IgA nephropathy
Complement activation in IgA nephropathy
IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important contributor to IgA nephropathy pathology. In particular, multiple associations have been identified between complement alternative, lectin and terminal pathway proteins and IgA nephropathy severity. Recently, we have also gained insight into possible mechanisms that could link glomerular IgA deposition, complement activity, glomerular inflammation and disease severity. Ongoing clinical trials of therapeutic complement inhibitors will provide insight into the importance of complement activity to IgA nephropathy pathogenesis. Further research into mechanisms of complement activity is essential to improving our understanding and management of patients with IgA nephropathy.
Read abstract on library site Access full article
Featured Learning Zones
You may be interested in...
The 2023 update of the German Society of Neurology’s guideline on Parkinson’s disease (PD) provides detailed recommendations on the use of transcranial brain parenchyma sonography (TCS) for early and differential diagnosis. This update addresses previously unspecified diagnostic criteria and investigator qualifications, offering a robust framework based on a systematic literature review.